Lowering of serum cholesterol in hypercholesterolemic humans by tocotrienols (palmvitee). 1991

A A Qureshi, and N Qureshi, and J J Wright, and Z Shen, and G Kramer, and A Gapor, and Y H Chong, and G DeWitt, and A Ong, and D M Peterson
Advanced Medical Research, Madison, WI 53719.

A double-blind, crossover, 8-wk study was conducted to compare effects of the tocotrienol-enriched fraction of palm oil (200 mg palmvitee capsules/day) with those of 300 mg corn oil/d on serum lipids of hypercholesterolemic human subjects (serum cholesterol 6.21-8.02 mmol/L). Concentrations of serum total cholesterol (-15%), LDL cholesterol (-8%), Apo B (-10%), thromboxane (-25%), platelet factor 4 (-16%), and glucose (-12%) decreased significantly only in the 15 subjects given palmvitee during the initial 4 wk. The crossover confirmed these actions of palmvitee. There was a carry over effect of palmvitee. Serum cholesterol concentrations of seven hypercholesterolemic subjects (greater than 7.84 mmol/L) decreased 31% during a 4-wk period in which they were given 200 mg gamma-tocotrienol/d. This indicates that gamma-tocotrienol may be the most potent cholesterol inhibitor in palmvitee capsules. The results of this pilot study are very encouraging.

UI MeSH Term Description Entries
D008075 Lipoproteins, HDL A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases. High Density Lipoprotein,High-Density Lipoprotein,High-Density Lipoproteins,alpha-Lipoprotein,alpha-Lipoproteins,Heavy Lipoproteins,alpha-1 Lipoprotein,Density Lipoprotein, High,HDL Lipoproteins,High Density Lipoproteins,Lipoprotein, High Density,Lipoprotein, High-Density,Lipoproteins, Heavy,Lipoproteins, High-Density,alpha Lipoprotein,alpha Lipoproteins
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008078 Cholesterol, LDL Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol. LDL Cholesterol,Cholesteryl Linoleate, LDL,LDL Cholesteryl Linoleate,Low Density Lipoprotein Cholesterol,beta-Lipoprotein Cholesterol,Cholesterol, beta-Lipoprotein,beta Lipoprotein Cholesterol
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D010978 Platelet Factor 4 A CXC chemokine that is found in the alpha granules of PLATELETS. The protein has a molecular size of 7800 kDa and can occur as a monomer, a dimer or a tetramer depending upon its concentration in solution. Platelet factor 4 has a high affinity for HEPARIN and is often found complexed with GLYCOPROTEINS such as PROTEIN C. Antiheparin Factor,CXCL4 Chemokine,Chemokine CXCL4,Heparin Neutralizing Protein,PF4 (Platelet Factor 4),gamma-Thromboglobulin,CXCL4, Chemokine,Chemokine, CXCL4,gamma Thromboglobulin
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D002839 Chromans Benzopyrans saturated in the 2 and 3 positions. Dihydrobenzopyrans
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked

Related Publications

A A Qureshi, and N Qureshi, and J J Wright, and Z Shen, and G Kramer, and A Gapor, and Y H Chong, and G DeWitt, and A Ong, and D M Peterson
July 1991, Atherosclerosis,
A A Qureshi, and N Qureshi, and J J Wright, and Z Shen, and G Kramer, and A Gapor, and Y H Chong, and G DeWitt, and A Ong, and D M Peterson
January 2007, Alternative therapies in health and medicine,
A A Qureshi, and N Qureshi, and J J Wright, and Z Shen, and G Kramer, and A Gapor, and Y H Chong, and G DeWitt, and A Ong, and D M Peterson
November 1969, Science (New York, N.Y.),
A A Qureshi, and N Qureshi, and J J Wright, and Z Shen, and G Kramer, and A Gapor, and Y H Chong, and G DeWitt, and A Ong, and D M Peterson
January 2004, Journal of medicinal food,
A A Qureshi, and N Qureshi, and J J Wright, and Z Shen, and G Kramer, and A Gapor, and Y H Chong, and G DeWitt, and A Ong, and D M Peterson
January 2012, Oxidative medicine and cellular longevity,
A A Qureshi, and N Qureshi, and J J Wright, and Z Shen, and G Kramer, and A Gapor, and Y H Chong, and G DeWitt, and A Ong, and D M Peterson
December 1997, Journal of the American College of Nutrition,
A A Qureshi, and N Qureshi, and J J Wright, and Z Shen, and G Kramer, and A Gapor, and Y H Chong, and G DeWitt, and A Ong, and D M Peterson
May 2006, European journal of pharmacology,
A A Qureshi, and N Qureshi, and J J Wright, and Z Shen, and G Kramer, and A Gapor, and Y H Chong, and G DeWitt, and A Ong, and D M Peterson
March 2002, European journal of pharmacology,
A A Qureshi, and N Qureshi, and J J Wright, and Z Shen, and G Kramer, and A Gapor, and Y H Chong, and G DeWitt, and A Ong, and D M Peterson
April 1994, Biological psychiatry,
A A Qureshi, and N Qureshi, and J J Wright, and Z Shen, and G Kramer, and A Gapor, and Y H Chong, and G DeWitt, and A Ong, and D M Peterson
March 1997, Metabolism: clinical and experimental,
Copied contents to your clipboard!